Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer (AKT)
A Randomized, Double Blinding, Placebo-Controlled Clinical Trials of CD8+NKG2D+ AKT Cell Immunotherapy to the Pancreatic Cancer Patients Treated With Adjuvant Chemotherapy
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
This EARLY_PHASE1 trial investigates Pancreatic Ductal Adenocarcinoma and is currently ongoing. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown EARLY_PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status EARLY_PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Unknown Status EARLY_PHASE1
Status: Recruiting → Unknown Status
-
Jun 2018 — Sep 2019 [monthly]
Recruiting EARLY_PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Recruiting EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting Phase 0
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
For direct contact, visit the study record on ClinicalTrials.gov .